Barings’s PDL BioPharma, Inc. PDLI Stock Holding History

Barings’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-64,400	Closed	-$189K	–	985
2018 Q1	$189K	Hold	64,400	–	–	﹤0.01%	890
2017 Q4	$176K	Hold	64,400	–	–	﹤0.01%	929
2017 Q3	$218K	Hold	64,400	–	–	﹤0.01%	823
2017 Q2	$159K	Hold	64,400	–	–	﹤0.01%	827
2017 Q1	$146K	Hold	64,400	–	–	﹤0.01%	894
2016 Q4	$137K	Hold	64,400	–	–	﹤0.01%	859
2016 Q3	$216K	Hold	64,400	–	–	0.01%	747
2016 Q2	$202K	Sell	64,400 -25,400	-28%	-$84.7K	0.01%	862
2016 Q1	$299K	Buy	89,800 +26,700	+42%	+$83.2K	0.01%	808
2015 Q4	$223K	Hold	63,100	–	–	0.01%	850
2015 Q3	$317K	Buy	63,100 +52,400	+490%	+$300K	0.01%	744
2015 Q2	$69K	Hold	10,700	–	–	﹤0.01%	961
2015 Q1	$75K	Sell	10,700 -1,500	-12%	-$10.9K	﹤0.01%	950
2014 Q4	$94K	Hold	12,200	–	–	﹤0.01%	923
2014 Q3	$91K	Sell	12,200 -4,200	-26%	-$39K	﹤0.01%	939
2014 Q2	$159K	Sell	16,400 -2,200	-12%	-$19.6K	﹤0.01%	943
2014 Q1	$155K	Hold	18,600	–	–	﹤0.01%	895
2013 Q4	$157K	Sell	18,600 -3,100	-14%	-$26.1K	0.01%	891
2013 Q3	$173K	Buy	+21,700	New	+$174K	0.01%	895

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Barings's PDLI Position: Q2 2018 in Review

Barings sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 64,400 shares — an estimated $189K sold.

Barings first reported a position in PDLI in Q3 2013 and held it in 19 quarters. The position peaked at $317K in Q3 2015. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

Barings reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
Barings sold 64,400 PDL BioPharma, Inc. shares in Q2 2018, an estimated $189K.
Barings first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 19 quarters.
Barings's PDL BioPharma, Inc. position peaked at $317K in Q3 2015.
163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on Barings's 13F filing for Q2 2018, filed 3 Aug 2018.